Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Zinecard Generic Name & Formulations
Legal Class
Rx
General Description
Dexrazoxane 250mg, 500mg; per vial; pwd for IV infusion after reconstitution and dilution.
Pharmacological Class
Chelating agent.
How Supplied
Single-use vial—1 (w. diluent)
Manufacturer
Generic Availability
YES
Zinecard Indications
Indications
To reduce the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300mg/m2 and will continue to receive doxorubicin therapy to maintain tumor control.
Zinecard Dosage and Administration
Adult
Give by slow IV push or rapid drip IV infusion. Doxorubicin should be administered within 30 minutes after starting Zinecard infusion. Administer in 10:1 ratio (eg, 500mg/m2 Zinecard: 50mg/m2 doxorubicin). Renal impairment (CrCl <40mL/min): reduce ratio to 5:1 (eg, 250mg/m2 Zinecard: 50mg/m2 doxorubicin). Hepatic impairment: may need to reduce doxorubicin dose, therefore Zinecard dose must be reduced (maintaining 10:1 ratio).
Children
Not recommended.
Zinecard Contraindications
Contraindications
Chemotherapy regimens that do not contain an anthracycline.
Zinecard Boxed Warnings
Not Applicable
Zinecard Warnings/Precautions
Warnings/Precautions
Not recommended for use with initiation of doxorubicin. Renal or hepatic impairment. Monitor cardiac function and for myelosuppression; obtain CBCs frequently. Pregnancy (Cat.D); avoid. Nursing mothers: not recommended.
Zinecard Pharmacokinetics
See Literature
Zinecard Interactions
Not Applicable
Zinecard Adverse Reactions
Adverse Reactions
Inj site pain, myelosuppression, possible secondary malignancies (see literature).
Zinecard Clinical Trials
See Literature
Zinecard Note
Not Applicable
Zinecard Patient Counseling
See Literature
